Want to see IN:CONCORDBIO full AI Analyst Report?
Concord Biotech Ltd. (CONCORDBIO) Ratios
Concord Biotech Ltd. Ratios
IN:CONCORDBIO's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:CONCORDBIO's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.39 | 6.17 | 6.30 | 3.79 | 4.08 |
| Quick Ratio | 5.46 | 4.87 | 4.84 | 2.69 | 2.82 |
| Cash Ratio | 0.08 | 0.01 | 0.11 | 0.02 | 0.00 |
| Solvency Ratio | 1.53 | 1.92 | 2.07 | 1.31 | 1.07 |
| Operating Cash Flow Ratio | 1.59 | 1.34 | 1.87 | 1.28 | 1.34 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 649.20 | 42.61 | 9.84 | 7.07 |
| Net Current Asset Value | $ 10.31B | $ 9.14B | $ 7.22B | $ 5.04B | $ 4.23B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.05 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.06 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Financial Leverage Ratio | 1.11 | 1.12 | 1.11 | 1.17 | 1.19 |
| Debt Service Coverage Ratio | 1179.28 | 273.97 | 35.71 | 7.93 | 6.07 |
| Interest Coverage Ratio | 1034.40 | 577.89 | 166.74 | 56.71 | 67.85 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.25 | 0.38 | 1.23 | 3.89 | 6.56 |
| Net Debt to EBITDA | -0.03 | 0.00 | -0.01 | 0.08 | 0.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.87% | 64.03% | 65.61% | 77.49% | 75.89% |
| EBIT Margin | 32.70% | 38.34% | 38.03% | 35.15% | 32.12% |
| EBITDA Margin | 39.76% | 42.72% | 43.13% | 41.33% | 38.97% |
| Operating Profit Margin | 27.77% | 50.16% | 51.26% | 60.71% | 58.38% |
| Pretax Profit Margin | 32.67% | 41.21% | 40.57% | 37.74% | 33.32% |
| Net Profit Margin | 24.73% | 30.97% | 30.30% | 28.14% | 24.54% |
| Continuous Operations Profit Margin | 24.57% | 30.97% | 30.30% | 28.14% | 24.54% |
| Net Income Per EBT | 75.70% | 75.15% | 74.68% | 74.56% | 73.65% |
| EBT Per EBIT | 117.65% | 82.15% | 79.15% | 62.17% | 57.06% |
| Return on Assets (ROA) | 11.68% | 18.27% | 18.12% | 15.86% | 13.33% |
| Return on Equity (ROE) | 12.93% | 20.50% | 20.18% | 18.61% | 15.86% |
| Return on Capital Employed (ROCE) | 14.18% | 32.54% | 33.44% | 39.18% | 35.96% |
| Return on Invested Capital (ROIC) | 10.66% | 24.42% | 24.85% | 28.66% | 25.79% |
| Return on Tangible Assets | 11.68% | 18.28% | 18.12% | 15.86% | 13.36% |
| Earnings Yield | 2.43% | 2.14% | 1.98% | 2.43% | 1.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.29 | 2.30 | 2.91 | 2.73 | 2.75 |
| Payables Turnover | 6.02 | 3.82 | 3.70 | 2.05 | 2.07 |
| Inventory Turnover | 1.88 | 1.80 | 1.68 | 0.90 | 0.88 |
| Fixed Asset Turnover | 1.22 | 1.42 | 1.29 | 1.11 | 1.11 |
| Asset Turnover | 0.47 | 0.59 | 0.60 | 0.56 | 0.54 |
| Working Capital Turnover Ratio | 1.04 | 1.41 | 1.58 | 1.68 | 1.46 |
| Cash Conversion Cycle | 292.82 | 265.71 | 243.95 | 359.08 | 370.68 |
| Days of Sales Outstanding | 159.23 | 158.66 | 125.48 | 133.87 | 132.87 |
| Days of Inventory Outstanding | 194.25 | 202.63 | 217.02 | 403.45 | 414.25 |
| Days of Payables Outstanding | 60.66 | 95.57 | 98.55 | 178.24 | 176.44 |
| Operating Cycle | 353.48 | 361.28 | 342.50 | 537.32 | 547.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 25.58 | 23.65 | 25.38 | 23.51 | 19.83 |
| Free Cash Flow Per Share | 16.54 | 13.02 | 17.18 | 9.65 | 4.97 |
| Dividend Paid and CapEx Coverage Ratio | 1.30 | 1.22 | 1.69 | 1.24 | 0.92 |
| Capital Expenditure Coverage Ratio | 2.83 | 2.23 | 3.10 | 1.70 | 1.33 |
| Operating Cash Flow Coverage Ratio | 116.29 | 83.32 | 27.26 | 7.80 | 3.32 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.21 | 0.26 | 0.29 | 0.29 |
| Free Cash Flow Yield | 1.62% | 0.78% | 1.15% | 1.02% | 0.53% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 41.10 | 46.82 | 50.53 | 41.08 | 56.38 |
| Price-to-Sales (P/S) Ratio | 10.16 | 14.50 | 15.31 | 11.56 | 13.83 |
| Price-to-Book (P/B) Ratio | 5.32 | 9.60 | 10.20 | 7.65 | 8.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 61.58 | 127.69 | 86.60 | 97.74 | 189.79 |
| Price-to-Operating Cash Flow Ratio | 39.82 | 70.31 | 58.65 | 40.09 | 47.54 |
| Price-to-Earnings Growth (PEG) Ratio | -1.36 | 2.27 | 1.78 | 1.10 | -2.21 |
| Enterprise Value Multiple | 25.54 | 33.93 | 35.49 | 28.05 | 35.72 |
| Enterprise Value | 107.11B | 173.98B | 155.63B | 98.91B | 99.25B |
| EV to EBITDA | 25.54 | 33.93 | 35.49 | 28.05 | 35.72 |
| EV to Sales | 10.15 | 14.50 | 15.30 | 11.59 | 13.92 |
| EV to Free Cash Flow | 61.51 | 127.71 | 86.57 | 98.01 | 190.98 |
| EV to Operating Cash Flow | 39.78 | 70.32 | 58.63 | 40.21 | 47.84 |
| Tangible Book Value Per Share | 191.22 | 173.17 | 145.90 | 123.29 | 105.11 |
| Shareholders’ Equity Per Share | 191.57 | 173.27 | 145.93 | 123.31 | 105.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.25 | 0.25 | 0.25 | 0.26 |
| Revenue Per Share | 100.19 | 114.71 | 97.21 | 81.55 | 68.15 |
| Net Income Per Share | 24.78 | 35.52 | 29.45 | 22.95 | 16.72 |
| Tax Burden | 0.76 | 0.75 | 0.75 | 0.75 | 0.74 |
| Interest Burden | 1.00 | 1.07 | 1.07 | 1.07 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.02 | 0.02 | 0.04 | 0.04 |
| SG&A to Revenue | 0.14 | 0.12 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.03 | 0.67 | 0.86 | 1.02 | 1.19 |
Currency in INR
